Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg Journal Article

  


Authors: Dang, C.; Hudis, C.
Article Title: Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg
Abstract: Breast cancer is one of the leading causes of cancer-related mortality, and a cure is desperately needed. Adjuvant chemotherapy with anthracycline-based regimens has been proven to decrease the risk of relapse and cancer-related mortality in women with early-stage breast cancer. The taxanes (paclitaxel and docetaxel) have been incorporated into several adjuvant chemotherapy regimens in recent studies. Some of these trials are now mature and have demonstrated a definitive benefit with the use of taxanes. Thus, taxanes should be incorporated into the adjuvant treatment of breast cancer. To date, the available data do not allow one to select a single best taxane, schedule, or overall regimen.
Keywords: adult; treatment outcome; aged; middle aged; survival analysis; clinical trial; review; doxorubicin; fluorouracil; paclitaxel; cancer adjuvant therapy; disease free survival; chemotherapy, adjuvant; chemotherapy; methotrexate; cancer staging; neoplasm staging; carboplatin; consensus; breast cancer; erythropoietin; anemia; blood toxicity; antineoplastic combined chemotherapy protocols; drug administration schedule; cyclophosphamide; vincristine; dose-response relationship, drug; breast neoplasms; cancer mortality; risk assessment; docetaxel; prednisolone; randomized controlled trials; tamoxifen; cancer relapse; epirubicin; taxoids; taxane derivative; estrogen receptor; trastuzumab; recombinant granulocyte colony stimulating factor; anthracycline; risk reduction; drug dose regimen; mastectomy, segmental; novel erythropoiesis stimulating protein; hormone receptor status
Journal Title: Clinical Breast Cancer
Volume: 7
Issue: 1
ISSN: 1526-8209
Publisher: Elsevier Inc.  
Date Published: 2006-04-01
Start Page: 51
End Page: 58
Language: English
DOI: 10.3816/CBC.2006.n.013
PUBMED: 16764744
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-33744988303&partnerID=40&md5=2972c79856815fc30c8abbdaa509eedf
Notes: --- - "Cited By (since 1996): 13" - "Export Date: 4 June 2012" - "CODEN: CBCLB" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Clifford Hudis
    905 Hudis
  2. Chau Dang
    271 Dang
Related MSK Work